198 related articles for article (PubMed ID: 31730266)
1. Run-in periods and clinical outcomes of antipsychotics in dementia: A meta-epidemiological study of placebo-controlled trials.
Hulshof TA; Zuidema SU; Gispen-de Wied CC; Luijendijk HJ
Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):125-133. PubMed ID: 31730266
[TBL] [Abstract][Full Text] [Related]
2. Subjective Versus Objective Outcomes of Antipsychotics for the Treatment of Neuropsychiatric Symptoms Associated with Dementia.
Vredeveld EJ; Hulshof TA; Zuidema SU; Luijendijk HJ
CNS Drugs; 2019 Sep; 33(9):933-942. PubMed ID: 31473979
[TBL] [Abstract][Full Text] [Related]
3. Baseline imbalances and clinical outcomes of atypical antipsychotics in dementia: A meta-epidemiological study of randomized trials.
Hulshof TA; Zuidema SU; van Meer PJK; Gispen-de Wied CC; Luijendijk HJ
Int J Methods Psychiatr Res; 2019 Mar; 28(1):e1757. PubMed ID: 30515916
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis.
Yunusa I; Alsumali A; Garba AE; Regestein QR; Eguale T
JAMA Netw Open; 2019 Mar; 2(3):e190828. PubMed ID: 30901041
[TBL] [Abstract][Full Text] [Related]
5. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials.
Ma H; Huang Y; Cong Z; Wang Y; Jiang W; Gao S; Zhu G
J Alzheimers Dis; 2014; 42(3):915-37. PubMed ID: 25024323
[TBL] [Abstract][Full Text] [Related]
7. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
Schneider LS; Dagerman KS; Insel P
JAMA; 2005 Oct; 294(15):1934-43. PubMed ID: 16234500
[TBL] [Abstract][Full Text] [Related]
8. The Mortality Risk of Conventional Antipsychotics in Elderly Patients: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.
Hulshof TA; Zuidema SU; Ostelo RW; Luijendijk HJ
J Am Med Dir Assoc; 2015 Oct; 16(10):817-24. PubMed ID: 25933724
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia.
Yury CA; Fisher JE
Psychother Psychosom; 2007; 76(4):213-8. PubMed ID: 17570959
[TBL] [Abstract][Full Text] [Related]
10. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
12. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials.
Schneider-Thoma J; Efthimiou O; Huhn M; Krause M; Reichelt L; Röder H; Davis JM; Salanti G; Leucht S
Lancet Psychiatry; 2018 Aug; 5(8):653-663. PubMed ID: 30042077
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?
Herrmann N; Lanctôt KL
Drug Saf; 2006; 29(10):833-43. PubMed ID: 16970508
[TBL] [Abstract][Full Text] [Related]
14. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
Ballard C; Hanney ML; Theodoulou M; Douglas S; McShane R; Kossakowski K; Gill R; Juszczak E; Yu LM; Jacoby R;
Lancet Neurol; 2009 Feb; 8(2):151-7. PubMed ID: 19138567
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
16. Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials.
Wolf A; Leucht S; Pajonk FG
Eur Arch Psychiatry Clin Neurosci; 2017 Apr; 267(3):187-198. PubMed ID: 27530185
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of atypical antipsychotics in elderly patients with dementia.
Tariot PN; Profenno LA; Ismail MS
J Clin Psychiatry; 2004; 65 Suppl 11():11-5. PubMed ID: 15264966
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotics for delirium.
Lonergan E; Britton AM; Luxenberg J; Wyller T
Cochrane Database Syst Rev; 2007 Apr; (2):CD005594. PubMed ID: 17443602
[TBL] [Abstract][Full Text] [Related]
19. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis.
Gillies D; Beck A; McCloud A; Rathbone J; Gillies D
Cochrane Database Syst Rev; 2005 Oct; (4):CD003079. PubMed ID: 16235313
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
